Dissolvable Microneedle Patches to Enable Increased Access to Vaccines against SARS-CoV-2 and Future Pandemic Outbreaks

O’Shea, Jesse; Prausnitz, Mark R.; Rouphael, Nadine

doi:10.3390/vaccines9040320

Cited by 40 publications

(25 citation statements)

References 78 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The global pandemic has revealed a need for technologies that enable rapid development and increased accessibility of vaccines for COVID-19 and emerging diseases. Although several platforms are under active investigation (Andorko and Jewell, 2017 ; Super et al , 2021), microneedle arrays (MNAs) are one existing biomaterials-based vaccination strategy whose development has been accelerated by the current pandemic (Kim et al , 2020 ; O'Shea et al , 2021 ).…”

Section: Microneedle Arrays Provide An Accessible and Highly Modular Platform For Vaccination Against Current And Emerging Infectious Dismentioning

confidence: 99%

The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response

Kapnick

2022

DNA and Cell Biology

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) public health crisis has reached critical mass, but interdisciplinary research efforts have provided the global community with the first effective medical intervention to fight the pandemic—COVID-19 vaccines. Two of the vaccines approved for use in the United States and Europe deliver nucleic acid in the form of mRNA, the success of which would not be possible without biomaterials. Lipid nanoparticle (LNP)-based mRNA vaccines, discussed in this perspective, protect nucleic acids from degradation and deliver cargo directly to the intracellular compartment of cells where it is translated into the antigenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein that triggers protective immune responses. Despite success of LNP-based mRNA vaccines thus far, the pandemic has highlighted the need for emerging technologies that enable rapid development and increased accessibility to vaccination. Microneedle arrays, also discussed in this study, provide features that could lower barriers to vaccine access in resource-poor regions. The ability to exchange antigens within arrays could also facilitate swift vaccine deployment as public health needs evolve (e.g., in response to SARS-CoV-2 variants or entirely new pathogens). Therefore, the COVID-19 pandemic has spotlighted the readiness and value of biomaterials for the prevention and management of disease outbreaks.

show abstract

Section: Microneedle Arrays Provide An Accessible and Highly Modular Platform For Vaccination Against Current And Emerging Infectious Dismentioning

confidence: 99%

The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response

Kapnick

2022

DNA and Cell Biology

View full text Add to dashboard Cite

show abstract

“…Owing to the large population of active antigen-presenting cells in the epidermis and dermis together, the microneedle approach could potentially reduce the dose of vaccine thereby might reduce the overall vaccination cost. The dissolvable microneedle matrix encapsulated vaccine candidates are also reported to be stable for long period without the stringent requirement of cold chain storage [24,25]. A recently published data on the investigation of microneedles for delivering SARS-CoV-2 antigen for COVID-19 vaccine is reported by Kim et al [26].…”

Section: Microneedle: Minimally Invasive Techniquementioning

confidence: 99%

Mucosal and transdermal vaccine delivery strategies against COVID-19

Kumar

2021

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Graphical abstract The years 2020 and 2021 have witnessed a COVID-19 pandemic caused by the SARS-CoV-2 virus. However, these years have also witnessed certain remarkable scientific achievements. Researchers across the globe have been trying extremely hard and accomplished in bringing vaccines a great variety of COVID-19 vaccines. Though the route of administration for the majority of these vaccines has been the intramuscular route (invasive), some laboratories are developing formulations intended for transmucosal and transcutaneous (non-invasive) administration, which are in the early phases of pre-clinical and clinical development. This short report discusses these unconventional formulations against COVID-19, in brief, to stress the importance of research in the field of drug delivery.

show abstract

“…Table 1 shows some nanosystems designs for diphtheria and a new DNA vaccine against SARS-CoV-2. Microneedles are undoubtedly the most developed devices to date in transdermal immunization [52]. Although recently a very low-cost microneedle-anchored electroporator device for immunization against SARS-CoV-2 was shown, there are still challenges to overcome [53].…”

Section: Transdermal Administration Based On Microneedlesmentioning

confidence: 99%

The Importance of Nanocarrier Design and Composition for an Efficient Nanoparticle-Mediated Transdermal Vaccination

et al. 2021

View full text Add to dashboard Cite

The World Health Organization estimates that the pandemic caused by the SARS-CoV-2 virus claimed more than 3 million lives in 2020 alone. This situation has highlighted the importance of vaccination programs and the urgency of working on new technologies that allow an efficient, safe, and effective immunization. From this perspective, nanomedicine has provided novel tools for the design of the new generation of vaccines. Among the challenges of the new vaccine generations is the search for alternative routes of antigen delivery due to costs, risks, need for trained personnel, and low acceptance in the population associated with the parenteral route. Along these lines, transdermal immunization has been raised as a promising alternative for antigen delivery and vaccination based on a large absorption surface and an abundance of immune system cells. These features contribute to a high barrier capacity and high immunological efficiency for transdermal immunization. However, the stratum corneum barrier constitutes a significant challenge for generating new pharmaceutical forms for transdermal antigen delivery. This review addresses the biological bases for transdermal immunomodulation and the technological advances in the field of nanomedicine, from the passage of antigens facilitated by devices to cross the stratum corneum, to the design of nanosystems, with an emphasis on the importance of design and composition towards the new generation of needle-free nanometric transdermal systems.

show abstract

Dissolvable Microneedle Patches to Enable Increased Access to Vaccines against SARS-CoV-2 and Future Pandemic Outbreaks

Cited by 40 publications

References 78 publications

The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response

The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response

Mucosal and transdermal vaccine delivery strategies against COVID-19

The Importance of Nanocarrier Design and Composition for an Efficient Nanoparticle-Mediated Transdermal Vaccination

Contact Info

Product

Resources

About